Literature DB >> 9858225

Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val.

W R Sperr1, S Walchshofer, H P Horny, M Födinger, I Simonitsch, R Fritsche-Polanz, I Schwarzinger, E Tschachler, C Sillaber, W Hagen, K Geissler, A Chott, K Lechner, P Valent.   

Abstract

A subset of patients with systemic mastocytosis (SM) develop acute myeloid leukaemia (AML). However, little is known about the biology of such leukaemias and their relationship to the mast cell (MC) lineage. We report on two female patients who suffered from SM and AML. According to FAB criteria, the leukaemias were classified as AML-M4 (patient 1) and AML-MO (patient 2). The coexistence of the two distinct neoplasms (AML and SM) was demonstrable by immunostaining of serial bone marrow (BM) sections with monoclonal antibodies (mAb). In particular, the MC infiltrates were found to react with mAb against MC-tryptase and MC growth factor receptor c-kit (CD117), but not with mAb to CD15 or CD34. In contrast, the AML blasts were immunoreactive for CD15 (patient 1) or CD34 (patient 2), but did not express tryptase. The c-kit point mutation Asp-->Val at codon 816, considered to play a role in the transformation of MC progenitors, was detected in patient 1 in a BM cell fraction containing 4% MC. However, no c-kit mutation was found in pure AML blasts (<1% MC). These findings argue against an evolution of the AML clone from neoplastic MC or MC-committed progenitors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858225     DOI: 10.1046/j.1365-2141.1998.01072.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

Review 1.  Mastocytosis and disorders of mast cell proliferation.

Authors:  Joanne K Simpson; Dean D Metcalfe
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

2.  One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes.

Authors:  Karl Sotlar; Luis Escribano; Olfert Landt; Stefanie Möhrle; Sonia Herrero; Antonio Torrelo; Ulrich Lass; Hans-Peter Horny; Burkhard Bültmann
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

3.  High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.

Authors:  Robert Fritsche-Polanz; Marika Fritz; Andrea Huber; Karl Sotlar; Wolfgang R Sperr; Christine Mannhalter; Manuela Födinger; Peter Valent
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

4.  Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia.

Authors:  K Sotlar; T Marafioti; H Griesser; J Theil; C Aepinus; R Jaussi; H Stein; P Valent; H P Horny
Journal:  Mol Pathol       Date:  2000-08

5.  A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Mi Hyun Bae; Hyun-Ki Kim; Chan-Jeoung Park; Eul-Ju Seo; Sang Hyuk Park; Young-Uk Cho; Seongsoo Jang; Hyun-Sook Chi; Kyu-Hyung Lee
Journal:  Ann Lab Med       Date:  2013-02-21       Impact factor: 3.464

6.  Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.

Authors:  Shuji Ueda; Hirokazu Ikeda; Masao Mizuki; Jun Ishiko; Itaru Matsumura; Hirokazu Tanaka; Hirohiko Shibayama; Hiroyuki Sugahara; Emi Takai; Xian Zhang; Takashi Machii; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.490

Review 7.  Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature.

Authors:  H-W Bernd; K Sotlar; J Lorenzen; R Osieka; U Fabry; P Valent; H-P Horny
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

8.  Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently.

Authors:  Shaoting Zhang; Liangying Zhang; Zongying Jiang; Yue Guo; Hui Zhao; Jianmin Sun
Journal:  Biochem Biophys Rep       Date:  2021-03-02

Review 9.  The serum tryptase test: an emerging robust biomarker in clinical hematology.

Authors:  Peter Valent; Wolfgang R Sperr; Karl Sotlar; Andreas Reiter; Cem Akin; Jason Gotlib; Hans-Peter Horny; Michel Arock
Journal:  Expert Rev Hematol       Date:  2014-08-28       Impact factor: 2.929

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.